Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Zevra Therapeutics (ZVRA) over the last 9 years, with Q3 2025 value amounting to $119.5 million.

  • Zevra Therapeutics' Total Non-Current Liabilities rose 277.57% to $119.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $119.5 million, marking a year-over-year increase of 277.57%. This contributed to the annual value of $124.0 million for FY2024, which is 2041.16% up from last year.
  • Latest data reveals that Zevra Therapeutics reported Total Non-Current Liabilities of $119.5 million as of Q3 2025, which was up 277.57% from $121.6 million recorded in Q2 2025.
  • Zevra Therapeutics' 5-year Total Non-Current Liabilities high stood at $124.0 million for Q4 2024, and its period low was $5.4 million during Q3 2021.
  • Its 5-year average for Total Non-Current Liabilities is $64.7 million, with a median of $47.2 million in 2023.
  • As far as peak fluctuations go, Zevra Therapeutics' Total Non-Current Liabilities tumbled by 9262.21% in 2021, and later surged by 67595.05% in 2022.
  • Quarter analysis of 5 years shows Zevra Therapeutics' Total Non-Current Liabilities stood at $5.8 million in 2021, then surged by 593.97% to $40.2 million in 2022, then skyrocketed by 156.26% to $103.0 million in 2023, then rose by 20.41% to $124.0 million in 2024, then fell by 3.66% to $119.5 million in 2025.
  • Its last three reported values are $119.5 million in Q3 2025, $121.6 million for Q2 2025, and $115.5 million during Q1 2025.